| P50 | author | Marie-Claude Boily | Q60729400 |
| | Nathalie Broutet | Q67155265 |
| | Karen Canfell | Q70389126 |
| | Kate Simms | Q82505122 |
| | Adam Keane | Q88641672 |
| | Emily A Burger | Q91828131 |
| | Freddie Bray | Q114414637 |
| | Jean-François Laprise | Q114572118 |
| | Élodie Bénard | Q114572119 |
| | Mélanie Drolet | Q114572120 |
| | Guillaume Gingras | Q114572122 |
| | Elena Fidarova | Q114572124 |
| | Mark Jit | Q30105761 |
| | David M Lambert | Q41124715 |
| | Megan Smith | Q57071587 |
| | Michel Alary | Q57889025 |
| | Michael Caruana | Q58886284 |
| P2093 | author name string | Jane J Kim | |
| | Raymond Hutubessy | |
| | Marc Brisson | |
| | Stephen Sy | |
| | Catherine Regan | |
| | Diep T N Nguyen | |
| | Paul J N Bloem | |
| | Fayad Elsheikh | |
| P2860 | cites work | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review | Q28294064 |
| | Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE | Q59137552 |
| | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 |
| | Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis | Q78879005 |
| | Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries | Q89481201 |
| | HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control | Q90035185 |
| | Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study | Q91841838 |
| | Global elimination of cervical cancer as a public health problem | Q91841853 |
| | Guidelines for multi-model comparisons of the impact of infectious disease interventions | Q92681113 |
| | A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women | Q30052389 |
| | Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities | Q33344903 |
| | Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection | Q33955573 |
| | An updated natural history model of cervical cancer: derivation of model parameters | Q34083083 |
| | Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 |
| | HPV screening for cervical cancer in rural India | Q34973414 |
| | Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior | Q36418125 |
| | Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease | Q36560944 |
| | The predicted impact of vaccination on human papillomavirus infections in Australia | Q37219650 |
| | Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study | Q38119752 |
| | Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials | Q38160099 |
| | The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. | Q38687001 |
| | Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study | Q39107868 |
| | HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer | Q39338815 |
| | Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 |
| | Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old girls against human papillomavirus | Q49990618 |
| | Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. | Q52739580 |
| | Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. | Q52745312 |
| | A Two-Step Markov Processes Approach for Parameterization of Cancer State-Transition Models for Low- and Middle-Income Countries. | Q53698583 |
| | When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. | Q54962711 |
| | Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. | Q55416595 |
| | Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country | Q56910734 |
| | Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of Screening | Q57027360 |
| | Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis | Q57089346 |
| | Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods | Q57797237 |
| | Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies | Q58299168 |
| P433 | issue | 10224 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| P304 | page(s) | 575-590 | |
| P577 | publication date | 2020-01-30 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries | |
| P478 | volume | 395 | |